前列腺癌患者循环雄激素生物活性降低。

Reduced circulating androgen bioactivity in patients with prostate cancer.

作者信息

Raivio Taneli, Santti Henrikki, Schatzl Georg, Gsur Andrea, Haidinger Gerald, Palvimo Jorma J, Jänne Olli A, Madersbacher Stephan

机构信息

Biomedicum Helsinki, Institute of Biomedicine, University of Helsinki, Helsinki, Finland.

出版信息

Prostate. 2003 May 15;55(3):194-8. doi: 10.1002/pros.10234.

DOI:10.1002/pros.10234

PMID:12692785

Abstract

BACKGROUND

Previous studies on immunoreactive androgen levels in serum have revealed equivocal associations with the risk of prostate cancer (CaP). The aim of this study was to compare serum biological androgen activity between men with newly diagnosed CaP and age-matched men with benign prostatic hyperplasia (BPH).

METHODS

Caucasian men with newly diagnosed, untreated CaP (n = 101) and age-matched patients with BPH (n = 103) were investigated. Serum androgen bioactivity (ABA) levels were measured using a recently developed recombinant cell bioassay.

RESULTS

In comparison to men with BPH, CaP patients with Gleason score >or=8 (n = 16) had lower serum ABA (P < 0.05), and patients with Gleason score <or=5 (P < 0.05) or >or=8 (P = 0.07) displayed suppressed ABA levels in relation to serum testosterone. As the entire group, men with CaP (n = 101) had significantly lower serum ABA than age-matched men with BPH (n = 103): median 3.0 nM (range, 0.8-6.4 nM) versus 3.2 nM (range, 0.8-7.9 nM) testosterone equivalents, respectively (P < 0.005). By contrast, serum immunoreactive testosterone and SHBG concentrations and free androgen indices did not differ significantly between the two groups.

CONCLUSIONS

Patients with CaP have lower serum ABA than controls with BPH, and men with low or high Gleason score display suppressed circulating ABA-to-testosterone ratio. These features may reflect interaction between variables such as the degree of tumor differentiation and tumor volume with androgen metabolism.

摘要

背景

既往关于血清中免疫反应性雄激素水平的研究显示，其与前列腺癌（CaP）风险的关联并不明确。本研究旨在比较新诊断的CaP患者与年龄匹配的良性前列腺增生（BPH）患者血清中的生物雄激素活性。

方法

对新诊断的未经治疗的CaP白种男性患者（n = 101）和年龄匹配的BPH患者（n = 103）进行研究。使用最近开发的重组细胞生物测定法测量血清雄激素生物活性（ABA）水平。

结果

与BPH患者相比，Gleason评分≥8分的CaP患者（n = 16）血清ABA较低（P < 0.05），Gleason评分≤5分（P < 0.05）或≥8分（P = 0.07）的患者相对于血清睾酮显示出ABA水平受到抑制。作为一个整体，CaP男性患者（n = 101）的血清ABA显著低于年龄匹配的BPH男性患者（n = 103）：分别为睾酮当量中位数3.0 nM（范围，0.8 - 6.4 nM）和3.2 nM（范围，0.8 - 7.9 nM）（P < 0.005）。相比之下，两组之间血清免疫反应性睾酮和SHBG浓度以及游离雄激素指数没有显著差异。